Vertex reported a positive phase 3 readout for povetacicept in immunoglobulin A nephropathy (IgAN) and is advancing regulatory filings. The company said the trial met its primary endpoint with a large reduction in proteinuria, and executives signaled plans for an expedited submission to the U.S. Food and Drug Administration. The asset was acquired as part of Vertex’s $4.9 billion purchase of Alpine Immune Sciences, and analysts flagged best‑in‑class commercial potential. The Phase 3 data included a substantial placebo‑adjusted drop in urine protein‑to‑creatinine ratio (UPCR) at interim analysis, a standard surrogate for kidney‑disease progression. Vertex intends to complete a biologics license application (BLA) and pursue accelerated pathways where applicable. Competing APRIL/BAFF inhibitors from Otsuka and Vera Therapeutics are already in late‑stage development, setting up a near‑term commercial race in a niche chronic kidney disease with high unmet need. Investors responded quickly to the results, lifting Vertex shares. Regulators will review safety and the robustness of proteinuria reduction as a basis for approval and any accelerated pathway; clinical and payer access strategies will determine eventual market uptake.